\contentsline {chapter}{\numberline {1}Introduction}{5}{chapter.1}
\contentsline {section}{\numberline {1.1}Cancer Research in the Post-Genomic Era}{5}{section.1.1}
\contentsline {subsection}{\numberline {1.1.1}Cancer as a Global Health Concern}{6}{subsection.1.1.1}
\contentsline {subsubsection}{\numberline {1.1.1.1}Genetics and Molecular Biology in Cancers}{7}{subsubsection.1.1.1.1}
\contentsline {subsection}{\numberline {1.1.2}The Human Genome Revolution}{9}{subsection.1.1.2}
\contentsline {subsubsection}{\numberline {1.1.2.1}The First Human Genome Sequence}{9}{subsubsection.1.1.2.1}
\contentsline {subsubsection}{\numberline {1.1.2.2}Impact of Genomics}{10}{subsubsection.1.1.2.2}
\contentsline {subsection}{\numberline {1.1.3}Technologies to Enable Genetics Research}{11}{subsection.1.1.3}
\contentsline {subsubsection}{\numberline {1.1.3.1}DNA Sequencing and Genotyping Technologies}{11}{subsubsection.1.1.3.1}
\contentsline {subsubsection}{\numberline {1.1.3.2}Microarrays and Quantitative Technologies}{12}{subsubsection.1.1.3.2}
\contentsline {subsubsection}{\numberline {1.1.3.3}Massively Parallel ``Next Generation'' Sequencing}{13}{subsubsection.1.1.3.3}
\contentsline {subsubsubsection}{\numberline {1.1.3.3.1}Molecular Profiling with Genomics Technology}{14}{subsubsubsection.1.1.3.3.1}
\contentsline {subsubsubsection}{\numberline {1.1.3.3.2}Established Sequencing Technologies}{15}{subsubsubsection.1.1.3.3.2}
\contentsline {subsubsubsection}{\numberline {1.1.3.3.3}Emerging Sequencing Technologies}{16}{subsubsubsection.1.1.3.3.3}
\contentsline {subsubsection}{\numberline {1.1.3.4}Bioinformatics as Interdisciplinary Genomic Analysis}{18}{subsubsection.1.1.3.4}
\contentsline {subsection}{\numberline {1.1.4}Follow-up Large-Scale Genomics Projects}{18}{subsection.1.1.4}
\contentsline {subsection}{\numberline {1.1.5}Cancer Genomes}{19}{subsection.1.1.5}
\contentsline {subsubsection}{\numberline {1.1.5.1}The Cancer Genome Atlas Project}{20}{subsubsection.1.1.5.1}
\contentsline {subsubsection}{\numberline {1.1.5.2}The International Cancer Genome Consortium}{21}{subsubsection.1.1.5.2}
\contentsline {subsubsubsection}{\numberline {1.1.5.2.1}Findings from Cancer Genomes}{21}{subsubsubsection.1.1.5.2.1}
\contentsline {subsubsubsection}{\numberline {1.1.5.2.2}Genomic Comparisons Across Cancer Tissues}{23}{subsubsubsection.1.1.5.2.2}
\contentsline {subsubsubsection}{\numberline {1.1.5.2.3}Cancer Genomic Data Resouces}{24}{subsubsubsection.1.1.5.2.3}
\contentsline {subsection}{\numberline {1.1.6}Genomic Cancer Medicine}{24}{subsection.1.1.6}
\contentsline {subsubsection}{\numberline {1.1.6.1}Cancer Genes and Driver Mutations}{25}{subsubsection.1.1.6.1}
\contentsline {subsubsection}{\numberline {1.1.6.2}Personalised or Precision Cancer Medicine}{26}{subsubsection.1.1.6.2}
\contentsline {subsubsubsection}{\numberline {1.1.6.2.1}Molecular Diagnostics and Pan-Cancer Medicine}{26}{subsubsubsection.1.1.6.2.1}
\contentsline {subsubsection}{\numberline {1.1.6.3}Targeted Therapeutics and Pharmacogenomics}{27}{subsubsection.1.1.6.3}
\contentsline {subsubsubsection}{\numberline {1.1.6.3.1}Targeting Oncogenic Driver Mutations}{27}{subsubsubsection.1.1.6.3.1}
\contentsline {subsubsection}{\numberline {1.1.6.4}Systems and Network Biology}{28}{subsubsection.1.1.6.4}
\contentsline {subsubsubsection}{\numberline {1.1.6.4.1} Network Medicine, and Polypharmacology}{31}{subsubsubsection.1.1.6.4.1}
\contentsline {section}{\numberline {1.2}A Synthetic Lethal Approach to Cancer Medicine}{32}{section.1.2}
\contentsline {subsection}{\numberline {1.2.1}Synthetic Lethal Genetic Interactions}{32}{subsection.1.2.1}
\contentsline {subsection}{\numberline {1.2.2}Synthetic Lethal Concepts in Genetics}{33}{subsection.1.2.2}
\contentsline {subsection}{\numberline {1.2.3}Studies of Synthetic Lethality}{34}{subsection.1.2.3}
\contentsline {subsubsection}{\numberline {1.2.3.1}Synthetic Lethal Pathways and Networks}{34}{subsubsection.1.2.3.1}
\contentsline {subsubsubsection}{\numberline {1.2.3.1.1}Conservation and Evolution of Synthetic Lethality}{35}{subsubsubsection.1.2.3.1.1}
\contentsline {subsection}{\numberline {1.2.4}Synthetic Lethal Concepts in Cancer}{36}{subsection.1.2.4}
\contentsline {subsection}{\numberline {1.2.5}Clinical Impact of Synthetic Lethality in Cancer}{37}{subsection.1.2.5}
\contentsline {subsection}{\numberline {1.2.6}High{}-throughput Screening for Synthetic Lethality}{39}{subsection.1.2.6}
\contentsline {subsubsection}{\numberline {1.2.6.1}Examples of Synthetic Lethal Screens}{41}{subsubsection.1.2.6.1}
\contentsline {subsection}{\numberline {1.2.7}Computational Prediction of Synthetic Lethality}{44}{subsection.1.2.7}
\contentsline {subsubsection}{\numberline {1.2.7.1}Bioinformatics approaches to gene interactions}{44}{subsubsection.1.2.7.1}
\contentsline {subsubsection}{\numberline {1.2.7.2}Comparative genomics}{45}{subsubsection.1.2.7.2}
\contentsline {subsubsection}{\numberline {1.2.7.3}Analysis and modelling of protein data}{48}{subsubsection.1.2.7.3}
\contentsline {subsubsection}{\numberline {1.2.7.4}Differential gene expression}{50}{subsubsection.1.2.7.4}
\contentsline {subsubsection}{\numberline {1.2.7.5}Data mining and machine learning}{51}{subsubsection.1.2.7.5}
\contentsline {subsubsection}{\numberline {1.2.7.6}Bimodality}{54}{subsubsection.1.2.7.6}
\contentsline {subsubsection}{\numberline {1.2.7.7}Rationale for further development}{54}{subsubsection.1.2.7.7}
\contentsline {section}{\numberline {1.3}E-cadherin as a Synthetic Lethal Target}{55}{section.1.3}
\contentsline {subsection}{\numberline {1.3.1}The \textit {CDH1} gene and it's Biological Functions}{55}{subsection.1.3.1}
\contentsline {subsubsection}{\numberline {1.3.1.1}Cytoskeleton}{55}{subsubsection.1.3.1.1}
\contentsline {subsubsection}{\numberline {1.3.1.2}Extracellular and Tumour Micro-Environment}{56}{subsubsection.1.3.1.2}
\contentsline {subsubsection}{\numberline {1.3.1.3}Cell-Cell Adhesion and Signalling}{56}{subsubsection.1.3.1.3}
\contentsline {subsection}{\numberline {1.3.2}\textit {CDH1} as a Tumour (and Invasion) Suppressor}{56}{subsection.1.3.2}
\contentsline {subsubsection}{\numberline {1.3.2.1}Breast Cancers and Invasion}{57}{subsubsection.1.3.2.1}
\contentsline {subsection}{\numberline {1.3.3}Hereditary Diffuse Gastric Cancer and Lobular Breast Cancer}{57}{subsection.1.3.3}
\contentsline {subsection}{\numberline {1.3.4}Somatic Mutations}{58}{subsection.1.3.4}
\contentsline {subsubsection}{\numberline {1.3.4.1}Mutation Rate}{58}{subsubsection.1.3.4.1}
\contentsline {subsubsection}{\numberline {1.3.4.2}Co-occuring Mutations}{59}{subsubsection.1.3.4.2}
\contentsline {subsection}{\numberline {1.3.5}Models of \textit {CDH1} loss in cell lines}{60}{subsection.1.3.5}
\contentsline {section}{\numberline {1.4}Summary and Research Direction of Thesis}{60}{section.1.4}
\contentsline {chapter}{\hbox to\@tempdima {\hfil }References}{64}{section.1.4}
